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Abbreviations   
ACS - acute coronary syndrome  
AF – atrial fibrillation   
AHF - acute heart failure  
AMI - acute myocardial infarction 
CI - confidence interval  
CKD - chronic kidney disease  
COPD - chronic obstructive pulmonary disease  
DM - diabetes mellitus  
HPT - hypertension  
IS - ischemic stroke  
MOOSE - Meta-analyses of Observational Studies in Epidemiology  
NOAC - non-vitamin K antagonist oral anticoagulants 
OAC - oral anticoagulants 
PRISMA - Preferred Reporting Items for Systematic Reviews and Meta-analyses  
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Abstract 
Background: Our previous review showed great variability on the incidence and prevalence 
of atrial fibrillation (AF) in non-Western cohorts, especially from Asian countries; in recent 
years, epidemiology studies on AF have been increasingly reported. 
Methods: We therefore conducted an updated systematic review, to present the current 
knowledge base of AF epidemiology in Asian countries since our prior review. We also 
explored AF incidence and the risk of stroke in AF using meta-analysis, with I
2
 testing the 
heterogeneity. Third, ‘real world’ antithrombotic drug use for ischemic stroke (IS) prevention 
associated with AF was studied. 
Results：?58 papers from 8 countries in Asia were finally included in our analysis. The 
summary annual incidence of AF was 5.38 (95% CI: 4.53-6.24, I
2
=99.5%, N=10) per 1000 
person-years and the IS annual risk in AF was 3.0% (1.60%-4.95%, I
2
=99.8%, N=8) when 
meta-analysis was performed on hospital- and community-based studies. Hospital- and 
community- based AF prevalence ranged from 0.37% to 3.56% and 2.8% to 15.8%, 
respectively. IS prevalence in AF ranged 1.9-6.0% and 0.36-28.3% in community and hospital 
studies, respectively. Warfarin use in Chinese is relatively low (1.0-4.1%) when compared 
with Japanese (49.1-70.0%) in community-based studies. The rate of warfarin use was <50% 
in hospital-based studies. 
Conclusions: AF incidence and prevalence has increased in recent years, though great 
variability still exists in Asian countries. Variability in annual IS risk in AF patients was 
apparent between hospital- and community-based studies. However, the rate of warfarin 
use was less than 50% in hospital studies from Asian countries.
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Introduction 
Atrial fibrillation (AF) is the most common arrhythmia in clinical practice, and is associated 
with an increased risk of stroke,
1
 heart failure
2
 and mortality.
3
 Much of AF epidemiology has 
been derived from Western cohorts in North America and Europe, but data from 
non-Western cohorts are increasing, and published in our systematic review conducted five 
years ago.
1
 
 
Our previous systematic review showed great variability on the incidence and prevalence of 
AF in non-Western cohorts, especially from Asian countries.
4,5
 In recent years, epidemiology 
studies on AF have been increasingly reported from Asia. 
 
We therefore conducted an updated systematic review, to present the current knowledge 
base of AF epidemiology by systematically reviewing the published literature in Asian 
countries in the recent five years, since our prior review. We also explored AF incidence and 
the risk of stroke in AF among Asian countries using meta-analysis. Third, ‘real world’ 
antithrombotic drug use for ischemic stroke (IS) prevention associated with AF was studied. 
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Materials and Methods 
Methods for our review were reported previously
1
, and this update replicates our previous 
approach. We followed Preferred Reporting Items for Systematic Reviews and Meta-analyses 
(PRISMA) and the Meta-analyses of Observational Studies in Epidemiology (MOOSE) 
guidelines, when performing this study.
6,7
 In brief, two reviewers (Y. B. and A. S.) searched 
PubMed for studies published from 1 January, 2011 to 19 September, 2016 using “atrial 
fibrillation”, ”epidemiology”, “prevalence”, “incidence”, “risk factors”, “stroke”, 
“thromboembolism”, “transient ischemic attack” and names of countries in Asia according to 
the definitions from World Health Organization. We also listed the incidence and prevalence 
of AF categorized by hospital- or community-based studies.
1
 Furthermore, risk factors for AF, 
risk of ischemic stroke (IS) in AF and antithrombotic therapy used for stroke prevention in AF 
were explored in our study. AF, including atrial flutter or not, was defined according to the 
definitions in the original papers. The same exclusion criteria were used for our search, 
including cohort size < 750, inclusion of diseases other than AF, and clinical trials, except for 
the language exceptions. Studies using both English and Chinese were eligible for our study. 
Studies using duplicate data source would be excluded except for the one with the longest 
follow-up or with the most recent or the main publications or during different periods or 
with additional data relevant to our study. 
 
We extracted the following baseline information from the studies except for the main 
objectives, such as authors, cohort size, inclusion criteria, study design, study period. 
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Statistical analysis 
 
STATA, version 12.0 (Stata Corp.) and Medcalc, version 16.5 were used for statistical analyses. 
The formula event rate = counts of events /person-years of observation was used in our 
meta-analysis. Mean follow-up period and number of included patients were multiplied to 
calculate person-years if not reported in the original papers. The third variable would be 
estimated in case of the other two provided variables. 95% confidence interval of event rate 
was calculated using Medcalc. Outcomes were compared using a fixed effects model or, 
random effects model according to whether heterogeneity was found. I
2 
index was used to 
quantify heterogeneity across studies,
8
 with values of ≤? 25%, 25% to 50%, and ≤?50% 
representing low, moderate and high degrees of heterogeneity, respectively. Begg’s 
correlation test was used to assess publication bias.
9,10
 Weighted regression of AF rates from 
community-based studies in relation to increasing age was performed to show the AF rate 
trends with age. A two-sided p value<0.05 was taken as statistically significant. 
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Results 
A flow-chart for the search process is shown in Figure 1. Of the identified papers, we 
included 58 studies from the initial 821 abstracts, including 23 hospital-based papers and 35 
community-based papers. The included papers were categorized based on studied countries, 
as Chinese cohorts(mainland China, Taiwan, Hongkong )28, Japan 13, South Korea 5, Middle 
East 5, Bahrain 1, India 3, Malaysia 1, and Turkey 2. 
 
Incidence of AF 
The summary annual incidence of AF was 5.38 (95% confidence interval [CI]: 4.53-6.24) per 
1000 person-years through meta-analyzing 8,190 AF and 3,883,205 person-years data from 
Asian countries (mainly from Chinese, Japanese and Korean) (e- Figure 1 and Table 1). No 
publication bias was observed according to Begg’s test (p=0.79). The pooled AF annual 
incidence in community-based studies was 4.70 (95% CI: 3.84-5.56) per 1000 person-years, 
after excluding two studies reporting the incidence of new-onset AF in hospital-based 
studies. One study from Japan showed that annual incidence of hospital-based AF was 9.4 
per 1000 person-year.
11
 The one study from South Korea showed AF incidence was 11.4 and 
8.9 per 1000 person-years in osteoporosis patients with and without bisphosphonate 
treatment, separately.
12
 
 
Community-based AF incidence varied between countries based on the eight studies.
13-20
 
For example, annual incidence ranged from 0.05 per 100 person-years to 4.90 per 1000 
person-years in the studies from China.
13,15,16
 AF incidence in men and women was 7.75 and 
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8.02 per 1000 person-years with a mean follow-up of 9.16 years, respectively.
14
 Annual 
incidence of AF ranged from 2.07 to 9.30 per 1000 person-years in Japan, 
17-19
 and was 3.21 
per 1000 person-years in one study from South Korea
20
.  
 
Community-based AF Prevalence  
The lowest AF prevalence reported was 0.03% in India
21
 and the highest reported was 3.75% 
in one study from China
22
 with the latter testing a stratified random cluster sampling 
method.  
 
Within each country, community-based AF prevalence varied from 0.37% to 3.75% in the 
nine studies from China
4,13,15,16,22-26
 and from 0.6% to 2.2% in the four studies from 
Japan.
27-30
 AF prevalence was relatively lower in India, from 0.03% to 0.5% based on three 
studies.
21,31
 
32
The prevalence of AF in South Korea
33
, Turkey 
34
 and Malaysia
35
 were 1.3%, 1.4% 
and 0.75%, respectively. The prevalence of AF was similar in South Korea and Turkey. (Figure 
2 and Table 2). The increasing AF rate in community-based studies with ageing is shown in 
e-Figure 3.” 
 
AF prevalence was usually higher in men than women among the majority 
studies.
16,22,24,25,29,33
 Two papers from Malaysia and a Chinese urban community reported 
similar AF prevalence between men and women.
23,35
 The same article from China showed a 
lower AF prevalence in men than women in rural community.
23
 This proportion remained 
low throughout the study period with no trends for an increase even in recent years 
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(e-Figure 4).
16,22-25,29,33,35
 AF prevalence increased with age in most studies,
15-17,22,25,29,33,35-37
 
except for one paper from China reporting no association between increased age and AF 
prevalence in rural community
23
 (Table 2). 
 
Multiple risk factors such as hyperuricemia,
13,37
 lack of regular activity
4,23
, 
alaninetransaminase,
33
 and adiponectin level
33
 all influenced the prevalence of AF, in 
additional to traditional factors, such as social demographic factors (age,
4,15,16,23,33
 
gender,
28,33
 body mass index
33
), history of stroke
23
, decreased renal function,
30,33
 and cardiac 
factors
23,28
 (rheumatic valvular diseases,
24
 myocardial infarction,
4,16,24,33
 left ventricular 
hypertrophy,
24
 low left ventricular ejection fraction),
4
 obesity,
24
 alcohol consumption,
24
 
hypertension (HPT),
16
 diabetes mellitus (DM)
4,28
 and abnormal cholesterol
23,28
. 
 
Hospital-based AF Prevalence 
AF prevalence in hospital-based studies was divided into two parts according to whether the 
report was in association with specific diseases. The general hospital-based prevalence of AF 
was reported in Japan (15.8%)
38
, Qatar (9.2%),
39
 and Bahrain (3.4%)
40
 respectively. 
Hospital-based AF prevalence was also higher in men than women in Japan (M:18.4% vs. 
W:11.7% and M:15.8% vs. W:8.8%). 
41,42
 In specific diseases as stroke (South Korea: M 15.9% 
vs. W 22.4%) and chronic obstructive pulmonary disease (COPD) (China: M 2.8% vs. W 5.2%), 
AF prevalence was lower in men than in women based on studies from South Korea
43
 and 
China.
44
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No reports were found on general hospital-based AF prevalence in Chinese cohorts, five 
studies on specific diseases, such as stable angina pectoris, chronic kidney disease (CKD), 
COPD, HPT combined with DM, and IS, associated AF prevalence were published.
44-48
 Three 
studies from middle eastern countries report AF prevalence associated with acute coronary 
syndrome (ACS, 2.7%),
49
 acute myocardial infarction(AMI,1.8%)
50
 and acute heart failure 
(AHF,12%),
51
 respectively. The first three common diseases associated with AF were stroke 
(18.6% in Korea),
43
 CKD (14.2% in China)
47
 and AHF (12% in seven Middle Eastern countries 
including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates, and Yemen)
51
 
(Figure 3 and e- Table 1). One hospital-based study reported that smoking was associated 
with AF prevalence.
41
 
 
Incidence and prevalence of IS in AF 
The pooled hospital-based incidence of IS in AF patients was 7.04(6.76-7.33, I
2
=0.0%) per 
100 person-years based on two papers from China,
52,53
 excluding the paper reporting only 
TE.
54
 The annual risk of IS in AF from community-based studies was 1.90%(-0.36%-4.17%, 
I
2
=99.9%, N=5).
29,55-58
 Annual IS risk in patients without antithrombotic was 4.9% in the 
community report from Taiwan.
59
 
 
Annual IS in AF without anticoagulants was 13.3 per 1000 person-years from one paper with 
mixed community- and hospital-based studies in Japan.
60
 When meta-analysis was 
performed based on hospital- and community- based studies, the IS annual risk in AF was 
3.0% (1.06%-4.95%,I
2
=99.8%,N=8), 
29,52,53,55-58,60
excluding the one paper with duplicate data 
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in Taiwan
59
 (e- Figure 2 and e-Table 2-3). No publication bias was seen based on Begg’s test. 
(p=0.25). 
 
Hospital-based IS prevalence in AF ranged 9.5% to 28.3% in studies from Chinese and Korean, 
52,54,61-63
 with one study data from an Emergency department, of 18.8%.
53
 No separate data 
on IS could be extracted from the paper with TE prevalence of 15.3% in Turkey.
64
 IS 
prevalence in AF is 0.49% (Arab) and 0.36% (south Asian) in hospital studies from Qatar.
65
 
Only two studies reported community-based IS prevalence in AF from China, ranging 1.9% to 
6.0%
16,25
 (e- Table 2-5). 
 
Use of Antithrombotic Therapy 
The use of warfarin in community-based studies from Chinese cohorts was very low, ranging 
1.0%-4.1%,
16,25,55
 while those from Japan was relatively high, ranging between 
49.1%-70.0%.
57,58
In Korea, rate of warfarin use kept stable, ranging 31.96% to 37.4% 
between 2001 and 2014.
66
 The rate of antiplatelet drugs use ranged widely within China 
(4.8-32.3%),
16,25,55
while similar within Japan (29.3-32.1%) in community-based studies. 
57,58
 
 
In Chinese cohorts, 8 hospital-based studies reported on warfarin anticoagulation, ranging 
from 9.4% to 33.3%
52-54,61,62,67-69
; however, therapy persistence was only 57.9% in those on 
oral anticoagulants (OAC) treatment during 1-year follow-up.
53
 In Turkey and Middle Eastern 
countries, the percentage of patients with warfarin treatment was less than 50% in 
hospital-based study.
64,65
 The use of antiplatelet drugs (mainly aspirin) in hospital-based 
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studies accounted for nearly half of AF patients, ranging 40.4% to 67.6%, whether in China, 
Turkey and Middle Eastern Countries.
52-54,61,62,64,65,69,70
 Five hospital-based studies reported 
the use of non-vitamin K antagonist oral anticoagulants (NOAC) in AF, ranging 0.6% to 
6.5%
58,61,62,69,70
 (e- Table 6). 
 
 
Discussion 
This updated systematic review found an incidence of AF in Asian countries of 5.38 per 1000 
person-year, after meta-analyzing 10 studies from 3 countries. Second, the variability was 
apparent in annual IS rate in AF patients between hospital- and community-based studies 
(7.04% vs. 1.90%). Third, the annual IS risk in AF patients with oral anticoagulants was lower 
than those without anticoagulation. However, reported rate of warfarin use was less than 50% 
in hospital from Asian countries. 
 
Most of the included studies assessed AF incidence and prevalence during the time period 
from the mid-2000s to mid-2010s. The overall and community-based incidence of new-onset 
AF in Asian countries was 5.38 and 4.70 per 1000 person-year, respectively, which increased 
greatly compared with data extracted from the previous systematic review including studies 
from 1990 to the mid-2000s.
1
 We partially ascribed this higher AF incidence to increasing 
age among Asian populations,
71
 which is also consistent with a progressive increase in the 
worldwide prevalence and incidence of AF.
71
 Though this could be confirmed in most 
included studies, which demonstrated increased AF prevalence with age (e- Figure 3), a large 
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population based prevalence study with adequate follow up duration is still needed in Asia. 
Furthermore, the community-based AF prevalence was broadly similar [0.1% to 4%], but 
hospital- based AF prevalence was a little higher [2.8% to 14%] when compared to that 
reported in prior analysis.
1
  
 
The community-based AF prevalence also varied widely among Asian countries (ranging 0.03% 
to 3.75%) or even within the same country as China (0.37% to 3.75%)
4,13,15,16,22-26
 and Japan 
(0.6% to 2.2%).
27-30
 The AF prevalence in India (0.03% to 0.5%)
21,31,32
 and Malaysia (0.75%)
35
 
was low, partly due to the selected healthy subjects or younger outpatients in the original 
studies.
21,31,35
 
32
To truly reflect the community-based AF prevalence, observational studies 
on populations with broader ages may be needed in India and Malaysia. AF prevalence in 
South Korea (1.3%), and Turkey (1.4%) were broadly similar to that reported from Europe 
and North American (1-2%).
72,73
 
 
Although the community-based AF prevalence in China (0.37%-3.56%)
4,13,15,16,22-26
 was 
relatively high, prevalent oral anticoagulant use (1.0%-4.6%)
16,25,55
 was lower compared with 
other Asian countries. This prevalence was generally higher compared with older data 
(0.5%-2.7%).
74,75
 There was low persistence of OAC use (57.9%) after prescription in 
hospital,
53
 which ranged from 9.4% to 33.3 %.
52-54,61,62,67-69
 Data on NOAC use in AF was 
generally limited although they have been introduced into clinical practice for more than five 
years,
76
 especially in the community-based studies from Asia. Hospital-based papers in China 
reported a low use of NOACs, ranging from 0.6 % to 6.5%.
58,61,62,69,70
 Unsurprisingly, 
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community-based IS rates associated with AF were higher in Chinese cohorts compared to 
other Asian countries after meta-analysis (3.1% vs. 1.9%).  
 
Stroke risk related to AF is usually reduced by approximately 64% with the use of OACs (eg. 
warfarin), and a further 19% reduction could be obtained with NOACs compared to 
warfarin.
77
 Unfortunately, the proportion of NOAC use was low throughout the study period 
in Asian countries and no trend showing an increase was seen, even in more recent years. 
Asians also tend to have a higher risk of haemorrhagic stroke compared to non-Asians, 
especially when on warfarin. In one recent US study, warfarin use with TTR ≥55% was 
associated with a 77% lower risk of stroke/SE compared to no antithrombotic therapy
78
; 
however, information on TTR and outcomes in the Asian studies we reviewed were limited. 
 
One different result from prior studies was the inconsistent AF prevalence between men and 
women, when studies were categorized into urban and rural settings. AF prevalence was 
higher in women in Chinese rural regions than men, while similar in Chinese urban regions
23
 
and Malaysia.
35
 The study by Wong et at
35
 focused on a specific population of patients with 
hypertension, while the study by Chei et al.
23
 mainly focused on elderly populations. 
Therefore, it would be difficult to draw any definitive conclusions due to baseline differences 
among studies which may account for the differences in AF prevalence between men and 
women in urban and rural settings. Other associated comorbidities, such as hyperuricemia 
and alcohol drinking have been highlighted, in addition to more traditional risk factors.
13,37
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Limitations 
Unsurprisingly, interpretation of the collected data would be difficult, since each study is 
heterogeneous: variability of incidence/prevalence of AF in Asian countries may be mainly 
due to differences in age distribution and diagnostic strategies between developed and 
developing countries.  
The incidence and prevalence of events (both AF and IS in AF) were generally lower in 
community-based studies, and underestimation may be a possibility, especially since 
asymptomatic AF is often neglected by the patients and paroxysmal AF could be missed with 
‘one off’ ECG recordings that were commonly used in most studies.
4,16,21-25,27-30,33,35
. Also, we 
were unable to draw any conclusions on AF incidence and risk factors such as obesity and 
uncontrolled hypertension, due to lack of detail in the published papers reviewed. 
 
Furthermore, heterogeneity was evident in meta-analysis of event rates, which was mainly 
caused by the variation in studied regions, mean ages, representative populations ethnic 
differences, and the various detection method, including - for example - health insurance 
claims
14
, AF on ECG during a follow up visit
16,17,19
 or during inpatient hospitalization
15
, ICD-9 
Code indicating AF at >2 outpatient visits or 1 inpatient visit
20
, Holter monitoring
11
, and no 
details on AF event capture provided
13
.  However, the outcomes of the included studies are 
broadly consistent which has reduces the risk of bias.
79
 In our previous review, this potential 
marked heterogeneity has been acknowledged and hence, our result was not presented 
after a meta-analysis. Despite these limitations, our findings provide a detailed summary 
and comparison for AF and its associated IS epidemiology in Asia, which may play a role in 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 16
healthcare policy and decision making in developing countries. 
 
Conclusions 
AF incidence and prevalence has increased in recent years, though great variability still exists 
in Asian countries. Variability in annual IS risk in AF patients was evident between hospital- 
and community-based studies. However, the rate of warfarin use was less than 50% in 
hospital studies from Asian countries.  
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Figure Legends 
 
Figure 1 PRISMA flow diagram of Selection Process. 
AF, atrial fibrillation; IS, ischemic stroke; N, number. 
 
Figure 2 AF prevalence in community-based studies. 
AF, atrial fibrillation. 
 
Figure 3 AF prevalence in hospital-based studies. 
AF, atrial fibrillation; Middle Eastern countries refer to 6 adjacent Arabian Gulf countries 
(Bahrain, Saudi Arabia, Qatar, Oman, United Arab Emirates and Yemen) in Hersi et al.; Qatar 
in Salam et al.; seven countries (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab 
Emirates and Yemen) in Sulaiman et al. and Bahrain in Garadah et al. 
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Table 1 Characteristics of the studies on incidence of AF in Asian countries 
Author Data source Period Study Size 
Age(mean/medi
an), y 
AF, N P-y eFollow-up,year 
Chuang,2014
14
 Elderly NAHSIT, Taiwan 1999-2000 1485 72.0 90 11,413 9.16  
Chao,2013
13
 NHIRD, Taiwan 2000- 2009 122,524 50.6 2,339 771,901 6.3  
Li,2015
16
 CDDMEP, China 2006-2011 3922 NA 34 6,939 3.8  
Guo,2015
15
 
 
Medical insurance database, 
Yunnan, China 
2001-2012 
 
471,446 
 
62 921 
 
1,924,975 
 
1.9  
 
Iguchi,2010
17
 
 
Kurashiki Public Health Center, 
Japan 
2006-2007 
 
30,449 
 
73 278 
 
29,893 
 
NA 
 
Watanabe,2011
19
 
Niigata, Japan NA 28,449 
59 
265 4,042 4.5  
Suzuki,2013
11
 Shinken Database, Japan 2004-2010 2,589 54.2 38 4,043 1.57 
Sano,2014
18
 CIRCS, Japan 1991-1995 7,206 56.0 296 45,790 6.4  
Kang,2016
20
 
National insurance program, 
Korea 
2003-2004 132,063 
52.6 
3,237 1,008,411 9.0  
Rhee,2012
12
 
 
Korean-HIRA, Korea 
 
2005-2006 
 
130,182 
 
72.95(B) 
72.64(O) 
626(B)  
66(O) 
5,773.4(B) 
70,025(O) 
NA 
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NAHSIT, Nutrition and Health Survey in Taiwan; NHIRD, National Health Insurance Research Database; 
CDDMEP: the Chronic Disease Detection and Management in the Elderly (≤?60 years) Program; 
CIRCS, the Circulatory Risk in Communities Study; HIRA, Health Insurance Review and Assessment; 
NA, not available; N, number; B, Bisphosphonate; O, other osteoporosis medication; eFollow-up, estimated follow-up; p-y, person-year; y, year; 
d, days. 
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Table 2 Baseline characteristics of included studies on community-based AF prevalence in Asian countries 
Author, 
year 
Period 
 
Data source 
 
Detection 
method 
Age,(mean
/median), 
y 
Male 
(%) 
Study 
Size 
AF, N  AF prevalence (%) Subgroup AF 
prevalence 
Lu,  
2012
25
 
Apr,2009- 
Jun,2010 
Xinjiang Kazaks, 
China  
Case history; ECG; 
Physical 
examination 
NA 44.01 
 
22,514 83 0.37%; 
M:0.59%：?W:0.2% 
Increase with age 
Chao,  
2013
13
 
2000-2009 
 
NHRID, Taiwan 
 
NA 50.6 73.7 122,524 2,339 1.9% Hyperuricemia:2.1%：? 
No hyperuricemia:1.7% 
Li,  
2013
24
 
2004 
 
 
Urban and rural, 
China 
 
Case history; 
Current ECG; 
Both  
NA 44.6 19,363 199 0.77%*; 
M: 0.78%#; 
W: 0.76%#. 
Urban :0.91%; 
Rural:0.67%; 
Increase with Age 
Chei,  
2015
23
 
1998-2012 
 
 
CLHLS, China 
 
Lead-I ECG 85.6 45.5 1,418 50 3.5%; 
M:2.4%; 
W:4.6%;  
 
Rural:4.6%;(M<W) 
No increase with age; 
Urban:2.3%.(M=W) 
Increase with Age 
Guo,2015
15
 2001-2012 Yun nan ,China NA 62 62 471,446 1,237 0.2% Increase with age 
Li,  
2015
16
 
2006-2011 
 
CDDMEP, China 12-lead ECG NA  43.8 3,922 70  
 
1.8%; 
M：?2.0%;W：?1.6% 
Increase with age  
Men> women 
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Sun,  
2015
4
 
Jan-Aug, 
2013 
 
rural Liaoning, 
China 
 
self-reported; 
ECG; 
Both 
NA 45.6 11,956 139 1.20% Hyperuricemia:2.4%; 
No hyperuricemia:1.0% 
Increase with age 
Miao,  
2015
22
 
NA 
 
  
Xinjiang, China 
 
12-lead ECG 
UCG 
Uygur: 
68.68  
Han: 
68.11  
49.3 5,398 192 Crude:3.56%; 
Stand :3.75%; 
Han:  
M:5.01%; W:3.31%; 
Uygur: 
M:3.19%;W:2.61% 
Increase with age 
Modesti, 
2016
26
 
2014 CHIP 
   
Single channel 
ECG 
41.7 44.4 1,608 
 
12 0.74% Increase with age 
Hingorani, 
2012
21
 
2005-2009 
 
Healthy volunteers, 
India   
12-lead ECG 31  62.7 3,978 1 0.025% NA 
Kalra, 
2015
31
 
Jan,2011- 
Feb,2014 
 
PIQIP, India 
 
NA 50.6 69.9 68,196 
 
348 0.5%; 
M:0.34% 
W:0.87% 
NA 
Saggu, NA Urban, Nagpur, 12-lead ECG 43.9  55.5 4,077 8 0.196% 
Increase with age 
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2015
32
 
India  
Iguchi, 
2010
28
 
2006- 
2007 
 
KAMS, Japan 
 
12-lead ECG 72 34.3 52,448 1161 2.20% Increase with age 
Iwahana, 
2011
29
 
Apr,1992- 
Jul,1995 
 
 
JMS, Japan 
  
12-lead ECG; 
Physical 
examination 
NA 37.9 10,929 54 AF: 54(0.9%) 
M: 30 (0.72%) 
W: 24 (0.35%) 
Increase with age 
Men > women 
Akao, 
2013
27
 
Mar,2011- 
Jun, 2012  
Fushimi-ku, Japan  
 
12-lead ECG; 
Holter 
74.2 59.3 283,000 3183 1.12% Young: paroxysmal; 
Older:  
persistent / permanent 
Ohyama, 
2013
30
 
Apr,2011- 
Mar,2012 
Gunma, Japan 
 
12-lead ECG 53.2 62 20,019 112 0.60% Increase with lower 
renal function 
Park,  
2015
33
 
Jan,2005- 
Dec,2009 
 
Yangpyeong, Korea, 
 
12-lead ECG 60.2 38.9 4,053 54 1.3%;  
M:2.0%; W: 0.9%. 
0.36%#; 
M: 0.45%#;W: 0.32%#. 
Increase with age 
M > W 
Wong, 
2012
35
 
Aug -Oct, 
2011 
Bumiputera 
Sarawak:78.2%; 
Home-health  
records;  
M: 55  
W: 51 
38.4 1,998 15 0.75% Increase with age 
M=W 
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NHIRD, National Health Insurance Research Database; CLHLS, the Chinese Longitudinal Healthy Longevity Survey; CDDMEP: the Chronic Disease 
Detection and Management in the Elderly (≤?60 years) Program; PIQIP, Practice Innovation and Clinical Excellence (PINNACLE) India Quality 
Improvement Program; KAMS, Kurashiki-city Annual Medical Survey; JMS, The Jichi Medical School; CHIP, Chinese in Prato. GRED, 
gastroesophageal reflux disease; HPT, hypertension;  
*, age-sex-adjusted AF prevalence;  # Age-adjusted AF prevalence;  C, Community;. 
 
 
 
 
 
 
Malay/Melanau: 
12.8%; 
Chinese:9%.  
12-lead ECG 
Albayrak, 
2015
34
 
NA 
 
MELEN study ,  
Turkey 
NA NA 38.1 1,495 21 1.4% NA 
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e-Table 1. Baseline Characteristics of studies on hospital-based AF prevalence in Asian countries 
 
Author, 
year 
Associated 
disease Period Data source  Study size 
Male Age(mean 
or median), 
y 
AF, N 
AF 
prevalence,  
(%) (%) 
Wei, 
COPD Jan,2000-Mar,2010 
PLA General 
Hospital, 
4,960 72 72.2 196 
3.9 
201127 Beijing Xiehe Hospital, M: 2.8; 
  Beijing 
Hospital, China W: 5.2. 
Lin, 
First IS Mar,2002-Dec,2008 
Department of 
Neurology,  
2,683 58.4 
AF:66.1; 366 13.6 
201128 
West China 
Hospital,  
No-AF: 
63.58. NVAF:213 NVAF:7.9 
  Sichuan 
University, 
China 
  
VAF:153 VAF:5.7 
Wang, 
CKD Jan,2006-Jun,2011 
Tertiary level 
Hospital, 1,168 54.5 63.3 166 14.2 
201329 Chongqing, China 
Xu, Stable AS Jan-Dec,2011 
Fuwai Hospital, 
China 2,541 69.5 
AF:68.6;  173 6.8 
201430 No AF:59.3 
Bao, 
HPT+DM Oct,2011-Jun, 2012 
36 Tertiary 
Hospital, China 15,914 49.7 64.6 1,174 7.4 201431 
Suzuki, 
NA 2004-2008 
Shinken 
Database, 
Japan 
11,123 61.7 M: 57.1; W: 60.7. 
1,131 15.8 
201232 M:811 M:18.4 
  W:320 W:11.7 
Suzuki, 
NA 2004-2011 
Shinken 
Database, 
Japan 
M:10,714 
61.2 
AF： M:1,698; M:15.80 
201333 W:6,803 M: 61.4; W: 69.3. W:598 W:8.8 
    No AF:     
    M: 58.1; 
W: 55.7. 
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Park, 
stroke Apr,2008-Jan,2011 CRCS, Korea 
9,417 
58 M: 64.8; W: 71.2. 
M:867; 18.6 
201434 (M:5,459; W:888 M:15.9; 
  W:3,958)   W:22.4 
Hersi, 
ACS Oct,2008-Jun, 2009 
Gulf RACE-2 
registry, 
7,930 78.7 56.8 217 2.7 
201135 Middle Eastern countries 
Salam, 
NA 1991-2010 Middle Eastern countries 41,453 NA NA 3,848 9.2 201236 
Salam, 
AMI 1991-2010 Middle Eastern countries 12,881 NA 
Arab: 58; 
227 1.8 
201337 Asian: 49. 
Sulaiman, 
AHF Feb-Nov,2012 
Gulf CARE,  
5,005 62.6 59;    607 12 
201538 Middle Eastern countries 
Garadah, 
NA Jan-Dec,2010 
ER, (Bahrain) 
7,450 NA NA 253 3.4 
201139 Middle Eastern countries  
 
Gulf CARE, Gulf aCuteheArt failuRe rEgistry; Gulf RACE-2 registry, the second Gulf Registry of Acute Coronary Events(including 
Bahrain, Saudi Arabia, Qatar, Oman, United Arab Emirates [UAE], and Yemen); ER, acute medical emergencies; CRCS, the Clinical 
Research Center for Stroke project; *, including Atrial Fibrillation and Atrial flutter; AMI, acute myocardial infarction; AHF, acute heart 
failure; AS, angina pectoris; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary diseases; HBP+DM, hypertension and 
diabetes mellitus; IS, ischemic stroke; ACS, acute coronary syndrome; NA, not available; M, men; W, women; N, number. 
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e-Table 2. Baseline characteristics of studies on incidence of Hospital-based ischemic stroke in Asian countries 
 
Author, 
year Period Data source 
Study 
size 
Male 
(%) 
Age(Mean/ 
median) , y 
Follow-
up IS, N(%) 
Yang, Nov,2008-
Oct,2011 
EDs in 20 
hospitals in China  2,016* 45.2 64.5 1-y 148(7.4%) 
201440 
Siu, Jul,1997-Dec, 
2011 
Queen Mary 
Hospital,  9,727 47.9 76.9 3.19y 2,179(22.4%) 
201441 Hong Kong 
Suzuki, Shinken:2004-2012; 
Shinken Database 
(N=1099),   
3,588 66.1 68.1 1.4 y 69 
201542# J-RHYTHM:  J-RHYTHM Registry(n=1002),  
  Jan -July 
2010; 
Fushimi AF 
Registry (n=1487) 
  Fushimi: 
Mar,2011- 
Without 
anticoagulants 
 
NHIRD, National Health Insurance research database in Taiwan; J-TRACE, the Japan Thrombosis Registry for Atrial Fibrillation, 
Coronary, or Cerebrovascular Events; J-RHYTHM, Investigation of optimal anticoagulation strategy for stroke prevention in Japanese 
patients with atrial fibrillation; Fushimi AF Registry, The Registry Study of Atrial Fibrillation Patients in Fushimi-ku; AFTER, Atrial 
Fibrillation in Turkey: Epidemiologic Registry; JMS, The Jichi Medical School cohort study; IS, ischemic stroke; AF, atrial fibrillation; 
ED, emergency department; N, number. * including atrial fibrillation and atrial flutter; #, with both hospital and community - based 
studies   
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e-Table 3. Baseline characteristics of studies on incidence of community-based ischemic stroke in Asian countries 
 
author, year Male (%) 
Age 
Period Data source Study size Follow-up 
IS, N 
(percentage, 
%) 
(Mean/median), 
y 
Guo, 
62 62 2001-2012 
Medical 
insurance 
database, 
Yunnan, China 
T:471,446 
11 y 59 
201543 AF:921 
Chang, 
56.7 74.5 
Jan, 2002-  NHIRD in 
Taiwan 
T:22,842,778 -Dec 31, 
2010 5183 
201444* Dec, 2004 AF:24,612 
Chao, 
54.6 
With 
stroke:73.4; Jan,2000- 
NHIRD in 
Taiwan,  
AF:7,601 3.0 ± 2.7 y,  
1116 
(14.7%)  
201445* No stroke:69.4 Dec,2009 
No 
antithrombotic 
agents 
Goto, 
68.7 70 NA J-TRACE, Japan AF:2,056 1 y -0.15% 201146 
Iwahana, 
55.6 
M:64.9;  Apr,1992- 
JMS, Japan 
T:10,929 
10.7 y 12 
201121 W:66.8. Jul,1995 AF:54  
Takabayashi, PAF:58; PAF:72.3; Mar,2011- 
The Fushimi 
AF Registry, 
Japan 
AF:3,304 
746 d 
IS : 
201547 SAF:61. SAF:74.9. Jul,2014 (PAF :1,588; No OAC: (1.4%); 
        
SAF :1,716) With OAC: (2.0%). 
 
*, the two papers using data from the same dataset. 
NHIRD, National Health Insurance research database in Taiwan; J-TRACE, Japan Thrombosis Registry for Atrial Fibrillation, Coronary, 
or Cerebrovascular Events;  JMS, The Jichi Medical School Cohort Study; J-RHYTHM, Investigation of optimal anticoagulation strategy 
for stroke prevention in Japanese patients with atrial fibrillation; Fushimi AF Registry, The Registry Study of Atrial Fibrillation Patients 
in Fushimi-ku; IS, ischemic stroke; AF, atrial fibrillation. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
	  
Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
e-Table 4. Baseline characteristics of studies on prevalence of hospital-based ischemic stroke in Asian countries 
 
Author, year Male (%) 
Age(mean/median),
y Period data source study size IS (percentage) 
Guo, 
58.2 64.8 
Jan,2008- 12 hospitals in 
Urumqi, China 1,310 125(9.5%) 201448 Dec,2012 
Yang, 
45.2 64.5 Nov,2008- Oct,2011 
20 representative 
ED, China 2,016* 379(18.8%) 201440 
Siu, 
47.9 76.9 Jul,1997- Dec, 2011 
Queen Mary 
Hospital,  9,727 2,295 (23.1%) 
201441 Hong Kong 
Guo, 
72.9 75 
Nov,2007- PLA General 
Hospital, China 1,034 209 (20.2%) 201349 Jul, 2010 
Sun, 
60.6 66.6 
Dec,2009- 29 Tertiary level 
Hospital, China  805 116(14.4%) 201450 Oct,2010 
Cha, 
66.3 
AF:66.6 Jan,2000- 
Korea 
T:1200; 
113(28.3%) 
201451 No-AF:65.83 May,2012 AF:400  
Salam, 
NA 
Arab:58; 
1991-2010 Middle Eastern countries 
Arab:2857  Arab: 14(0.49%) 
201352 Asian:49 Asian:548 Asian: 2(0.36%) 
Ertaş, 
39.8 80.3 NA 
AFTER 
2242 IS/TIA/SE:(15.3%) 
201353 
17 tertiary health 
care centers, 
Turkey (inpatient 
and ED excluded) 
 
ED, emergency department; AF, atrial fibrillation; IS, ischemic stroke; AFTER, Atrial Fibrillation in Turkey: Epidemiologic Registry;  
*, including atrial fibrillation and atrial flutter. 
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e-Table 5. Baseline characteristics of studies on prevalence of community-based ischemic stroke in Asian countries 
 
Author, 
year Male (%) 
Age , y 
Period Data source Study size Antithrombotic therapy IS, N (%) (Mean/median) 
Li, 20153 NA NA 2006-2011 CDDMEP 
T:3,922; Aspirin, 5 (4.8 %)  
2(1.9%) 
AF:104 Warfarin, 1 (1.0 %) 
Lu, 201211 44.01 NA 
Apr,2009- Xinjiang 
Kazaks, 
China 
T: 22,514 Warfarin, 2(2.4%) 
-6.00% 
Jun,2010 AF:83 Aspirin, 16(19.3%) 
 
NA, not available; CDDMEP: the Chronic Disease Detection and Management in the Elderly (≥60 years) Program;  
T, total patients; AF, atrial fibrillation; IS, ischemic stroke. 
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e-Table 6. Baseline characteristics of studies on OAC use in AF in Asian countries 
 
Author, year Period Data source Study size No OTA Antiplatelet Warfarin or OAC, 
N (%) 
NOACS, 
N(%) 
Chang, 2011-2014 CAFR 7,977     ChA2DS2-VASc 
score: 
  
201654 ≥2: (36.5%); 1: 
(28.5%); 
  0: (21.4%). 
Xiang, 2012-2013 Peking 
University 
First 
Hospital, 
China 
1,000 -31.40% -39.50% -27.80% -1.30% 
201555 
Xiong, 2011-2013 Nanchang 
AF project, 
China 
2,442     Pre-hospital: 173 
(7.3%); 
Hospitalization: 
791 (33.3%). 
  
201556 
Zhang, 2012-2015 AFAIS, 
China 
1,014 -22.50% -57.50% -9.40% -0.60% 
201657 
Guo, Jan,2008-
Dec,2012 
12 hospitals 
in Urumqi, 
China 
1,310*   655 (50.0%) 284 (21.7%) 54 (4.1%) 
201448 
Yang, Nov,2008-
Oct,2011 
20 EDs, 
China 
2,016# -24.70% 56.70% OAC : (8.6 %)   
201440 
  Baseline     OAC : (11.8 %)   
      1-y follow-up     OAC : (57.9 %)   
Siu, Jul,1997- 
Dec, 2011 
Queen Mary 
Hospital, 
Hong Kong 
9,727 -39.90% 40.40% -19.70%   
201441 
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Guo, Nov,2007-
Jul, 2010 
PLA General 
Hospital, 
China 
1,034 -18.00% -67.60% -14.40%   
201349 
Sun, Dec,2009-
Oct,2011 
29 Tertiary 
level 
Hospital, 
China 
805 -19.80% -51.60% -22.20% -6.50% 
201450 
Li, 2006-2011 CDDMEP T:3922;    5 of 104 (4.8 %) 1 of 104, (1.0 %)   
20153 AF: 104 
Guo, 2001-2012 medical 
insurance 
database, 
Yunnan 
T:471,446 
AF:921 
  298 of 921 38 of 921,(4.1%)   
201543 (32.3%); 
Lu, Apr,2009-
Jun,2010 
Xinjiang 
Kazaks, 
China 
T:22,514 ;   16 of 83, 
(19.3%) 
2 of 83, (2.4%)   
201211 AF:83 
Goto, NA J-TRACE 2,056   -30.10% -70.00%   
201146 
Takabayashi, Mar,2011- The Fushimi 
AF Registry 
3304   -29.30% -49.10%   
201547 Jul,2014 
      PAF :1588;    476 (30.0%); 557 (35.0%) D:51 
(3.0%);R:8 
(0.5%); 
Ap:2 (0.1%) 
      SAF :1716    492 (29.0%) 1066(62.0%) D:53 
(3.0%);R:13 
(0.8%); 
Ap:1 (0.1%) 
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Choi, 2011-2014 HIRA, 
Korea 
113,037     2011(31.9%); 
2012 (33.3%); 
  
201658 2013(35.7%); 
2014(37.4%). 
Salam, 1991-2010 Qatar 3,405          
201352  Middle 
eastern 
country 
Before 
Admission 
  1,055(31.0%) 56(1.6%)   
     During    1,786(52.5%) 615(18.1%)   
Admission 
     Discharge   1878(55.2%) 1124(33.0%)   
Ertaş,    17 tertiary 
health care 
centers, 
Turkey 
2242*   -60.00% (37.0%);   
201353 
 
*including non-valvular atrial fibrillation and valvular atrial fibrillation;#including atrial fibrillation and atrial flutter; CAFR, Chinese 
Atrial Fibrillation Registry; CDDMEP: the Chronic Disease Detection and Management in the Elderly (≥60 years) Program; AFAIS atrial 
fibrillation-associated ischemic stroke; NHIRD, National Health Insurance research database in Taiwan; J-TRACE, the Japan Thrombosis 
Registry for Atrial Fibrillation, Coronary, or Cerebrovascular Events; J-RHYTHM, Investigation of optimal anticoagulation strategy for 
stroke prevention in Japanese patients with atrial fibrillation; Fushimi AF Registry, The Registry Study of Atrial Fibrillation Patients in 
Fushimi-ku; HIRA ,Health Insurance Review and Assessment Service; AFTER ,Atrial Fibrillation in Turkey: Epidemiologic Registry; JMS, 
The Jichi Medical School cohort study; AFAIS, atrial fibrillation-associated ischemic stroke; ED, emergency department; AF, atrial 
fibrillation; A, aspirin; W, warfarin; D, dabigatran; R, rivaroxaban; Ap, apixaban; PAF, paroxysmal atrial fibrillation; SAF, persistent 
atrial fibrillation; OTA, oral antithrombotic agents therapy; OAC, oral anticoagulant agents therapy; NOACs, noval oral anticoagulant 
agents. 
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e- Figure 1. Annual incidence of atrial fibrillation in Asian Countries (events/1000 person-
years). 
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e- Figure 2. Annual rate of ischemic stroke in atrial fibrillation in both community- and 
hospital-based studies in Asian countries. 
 
OAC, oral anticoagulant agent. 
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e- Figure 3. Weighted regression of AF rate in community-based studies. 
 
This figure presents community-based AF rate with increasing age. The dashed line indicated 95% CI 
of the fitted line. The points indicated the separate AF rate with according age. AF, atrial fibrillation; 
CI, confidence interval. 
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e- Figure 4. Relative Risk of AF incidence between men and women in community-based 
studies. 
 
AF, atrial fibrillation; CI, confidence interval. 
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